论文信息 - Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy - 字舞流文

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

M. Heinrich | J. Cortes | D. DeAngelo | M. Talpaz | J. Janssen | M. Mauro | F. Mahon | A. Hochhaus | O. Ottmann | Varsha Iyer | Dong-Wook Kim | T. Hughes | M. Breccia | H. Minami | G. Vanasse | F. Lang | J. Steegmann | D. Réa | Y. Goh | David Hynds | Raina Duan | R. Duan | T. Hughes